IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Cone snails are prized for their brightly colored and patterned shells, which may tempt people to pick them up. This is risky, as the snail often fires its harpoon in self defense when disturbed. The harpoons of some of the larger species of cone snail can penetrate gloves or wetsuits. The sting of many of the smallest cone species may be no worse than a bee or hornet sting, but the sting of a few of the larger tropical fish-eating species, such as Conus geographus (geography cone), Conus tulipa and Conus striatus, can be fatal. Other dangerous species are Conus pennaceus, Conus textile, Conus aulicus, Conus magus and Conus marmoreus. According to Goldfrank's Toxicologic Emergencies, about 27 human deaths can be confidently attributed to cone snail envenomation, though the actual number is almost certainly much higher; some three dozen people are estimated to have died from geography cone envenomation alone. Most of the cone snails that hunt worms are not a risk to humans, with the exception of larger species. One of the fish-eating species, the geography cone, is also known colloquially as the "cigarette snail", a gallows humor exaggeration implying that, when stung by this creature, the victim will have only enough time to smoke a cigarette before dying. Symptoms of a more serious cone snail sting include severe, localized pain, swelling, numbness and tingling, and vomiting. Symptoms can start immediately or can be delayed for days. Severe cases involve muscle paralysis, changes in vision and respiratory failure that can lead to death.
=== Phase II === Study 980231 (Randomized, double-blind, placebo-controlled). Three dose regimens were included: "pre-post", "pre", and placebo Palifermin administration (60 micrograms/kg) by IV for three consecutive days before chemotherapy and after autologous peripheral blood progenitor cell (PBPC). Efficacy was demonstrated in the drug versus the placebo.
== Leucine starvation == Starvation induces the lysosomal retention of leucine such that it requires RAG-GTPases and the lysosomal protein complex regulator. PCAF is recruited specifically to the CHOP amino acid response element to enhance the ATF4 transcriptional activity.
In March 1946, a preliminary accord signed between the French and Ho Chi Minh which acknowledged the DRV as a free state within an Indochinese Federation in a "French Union" and allowed a limited number of French troops within its borders to replace the Chinese forces which started gradually returning to China. In further negotiations, the French would seek to ratify Vietnam's position within the Union and the Vietnamese main priorities were preserving their independence and the reunification with the Republic of Cochinchina, which had been created by High Commissioner Georges d'Argenlieu in June. In September, once main negotiations had broken down in Paris over these two key issues, Ho Chi Minh and Marius Moutet, the French Minister of the Colonies, signed a temporary modus vivendi which reaffirmed the March Accord, although no specifications were made on the issue of a Nam Bộ (Cochinchina) reunification referendum and negotiations for a definitive treaty were set to begin no later than January 1947. In the north, an uneasy peace had been maintained during the negotiations, in November however, fighting broke out in Haiphong between the Việt Minh government and the French over a conflict of interest in import duty at the port. On November 23, 1946, the French fleet bombarded the Vietnamese sections of the city killing 6,000 Vietnamese civilians in one afternoon. The Việt Minh quickly agreed to a cease-fire and left the cities. This is known as the Haiphong incident.
Sources: en.wikipedia.org
Protein adsorption is a process that has a fundamental role in the field of biomaterials. Indeed, biomaterial surfaces in contact with biological media, such as blood or serum, are immediately coated by proteins. Therefore, living cells do not interact directly with the biomaterial surface, but with the adsorbed proteins layer. This protein layer mediates the interaction between biomaterials and cells, translating biomaterial physical and chemical properties into a "biological language". In fact, cell membrane receptors bind to protein layer bioactive sites and these receptor-protein binding events are transduced, through the cell membrane, in a manner that stimulates specific intracellular processes that then determine cell adhesion, shape, growth, and differentiation. Protein adsorption is influenced by many surface properties such as surface wettability, surface chemical composition, and surface nanometre-scale morphology. Surfactant adsorption is a similar phenomenon, but utilising surfactant molecules in the place of proteins.
NAD-dependent deacetylase sirtuin-3, mitochondrial also known as SIRT3 is a protein that in humans is encoded by the SIRT3 gene. SIRT3 is member of the mammalian sirtuin family of proteins, which are homologs to the yeast Sir2 protein. SIRT3 exhibits NAD+-dependent deacetylase activity. Members of the sirtuin family are characterized by a sirtuin core domain and grouped into four classes, and the protein encoded by this gene is included in class I of the sirtuin family. The human sirtuins have a range of molecular functions and have emerged as important proteins in aging, stress resistance, and metabolic regulation. Yeast sirtuin proteins are known to regulate epigenetic gene silencing and suppress recombination of rDNA. In addition to protein deacetylation, studies have shown that the human sirtuins may also function as intracellular regulatory proteins with mono ADP ribosyltransferase activity.
Peak Identification: Before integration, the peaks corresponding to different components in the sample need to be identified, based on their retention times. This is typically done by comparing the observed peaks with known standards or reference data. Baseline Correction: Establish a baseline for the chromatogram, which represents the lowest signal level along the time axis next to the peak. The baseline represents the noise and background signal. Taking into account the baseline level allows an accurate integration, because it takes into account any drift or fluctuations in the baseline. Peak Integration parameters and settings: Use appropriate algorithms to integrate the peaks in the chromatogram. Adjust integration parameters and settings as needed, such as noting peak width, noise threshold, and baseline correction method, which determine where the peak starts and ends and its maximum point. Optimizing these parameters helps obtain accurate and precise integration results. Quantification: Once the areas under the peaks are determined through integration, the quantification of each component is performed. The integrated areas are compared to a calibration curve, created using standards' concentrations to calculate the concentration of each component in the unknown sample. Data Interpretation: The software analyzes the integrated data to draw conclusions about the composition, concentration, and purity of the sample. The integrated areas provide valuable information for various applications, including quality control, research, and analysis.
==== Pat Farrell's Alpha-Angle Freeze Mark ==== A specialized brand system is required to mark many animals such that each can be individually identified. Arabic numerals are difficult to brand much smaller than 4 inches (10 cm) tall. Further, conventional numbers can be altered, with a branded "3" easily turned into an "8," potentially shifting apparent ownership of the horse. It is also inconvenient to carry a dozen or more unique brands into the field if animals must be branded there.
=== Stress === Prolonged chronic stress may contribute to metabolic syndrome via dysregulation of the hypothalamic–pituitary–adrenal axis. Elevated cortisol can raise glucose and insulin levels, promoting visceral adiposity, insulin resistance, dyslipidaemia, and hypertension, and has effects on bone turnover.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.